Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Sponsor
Liu Huang
Study ID
NCT06551207
Status
Recruiting
Apply to this trial

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Fruquintinib — DRUG
    Fruquintinib:5mg ,qd,po, d1-d14, q3w
  • Cadonilimab — DRUG
    Cadonilimab:10mg/kg, ivgtt, d1, q3w
  • SBRT — RADIATION
    SBRT:8-10Gy×5F, god, in 10 days

Study Details

An assessment of 6-month progression-free survival in patients with mCRC with third-line and postline metastatic colorectal cancer in combination with cardonilizumab and fuquinitinib and SBRT compared with fuquinitinib monotherapy

Key Dates

First listed
Aug 13, 2024
Start date
Aug 20, 2024
Status verified
Aug 2024
Primary completion
Dec 30, 2026
Completion
Dec 30, 2027

Study Design

Enrollment
80 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: fuquintinib
  • Experimental: Fuquintinib combined with cardonilizumab and SBRT

Primary Outcome Measure

Progression-free survival [ Time Frame: 6mon-PFS ]

Central Contacts

Related Studies